Insulin Resistance & Nonalcoholic Fatty Liver Disease (NAFLD) / Nonalcoholic Steatohepatitis (NASH)
Seiten
2011
Nova Science Publishers Inc (Verlag)
978-1-61668-927-8 (ISBN)
Nova Science Publishers Inc (Verlag)
978-1-61668-927-8 (ISBN)
- Titel ist leider vergriffen;
keine Neuauflage - Artikel merken
The liver is the first organ to receive nutrients that enter the body via the intestines after a meal, and this organ plays a pivotal role in energy metabolism. This book reviews evidence concerning insulin resistance and NAFLD/NASH as a step towards a comprehensive understanding of the pathophysiology and treatment of NAFLD/NASH.
The liver is the first organ to receive nutrients that enter the body via the intestines after a meal, and this organ plays a pivotal role in energy metabolism. Non-alcoholic fatty liver disease (NAFLD) is among the most common causes of chronic liver disease in the world and is now considered to be a component of metabolic syndrome. A wide spectrum of histological changes has been observed in NAFLD, ranging from simple steatosis, which is generally non-progressive, to nonalcoholic steatohepatitis (NASH), liver cirrhosis, liver failure, and sometimes even hepatocellular carcinoma. This book reviews recent evidence concerning insulin resistance and NAFLD/NASH as a step towards a comprehensive understanding of the pathophysiology and treatment of NAFLD/NASH.
The liver is the first organ to receive nutrients that enter the body via the intestines after a meal, and this organ plays a pivotal role in energy metabolism. Non-alcoholic fatty liver disease (NAFLD) is among the most common causes of chronic liver disease in the world and is now considered to be a component of metabolic syndrome. A wide spectrum of histological changes has been observed in NAFLD, ranging from simple steatosis, which is generally non-progressive, to nonalcoholic steatohepatitis (NASH), liver cirrhosis, liver failure, and sometimes even hepatocellular carcinoma. This book reviews recent evidence concerning insulin resistance and NAFLD/NASH as a step towards a comprehensive understanding of the pathophysiology and treatment of NAFLD/NASH.
Introduction; NAFLD & Insulin Resistance (IR); Pathophysiology of NASH: Insulin Resistance, Free Fatty Acids & Cytokines; Adiponectin & NASH; TNF-a & NAFLD/NASH a; Leptin & NAFLD/NASH; Peroxisome Proliferators-Activated Receptors (PPARs) & NAFLD/NASH; Iron Overload & NAFLD/NASH; Mitochondrial Abnormalities & NAFLD/NASH; Genetic Influences in NAFLD / NASH; Therapeutic Strategy for NASH Patients; Natural History of NAFLD; Conclusions; Index.
| Erscheint lt. Verlag | 8.2.2011 |
|---|---|
| Verlagsort | New York |
| Sprache | englisch |
| Maße | 215 x 140 mm |
| Gewicht | 102 g |
| Themenwelt | Studium ► 1. Studienabschnitt (Vorklinik) ► Biochemie / Molekularbiologie |
| ISBN-10 | 1-61668-927-7 / 1616689277 |
| ISBN-13 | 978-1-61668-927-8 / 9781616689278 |
| Zustand | Neuware |
| Haben Sie eine Frage zum Produkt? |
Mehr entdecken
aus dem Bereich
aus dem Bereich
